A5080398668- Prostate Cancer Treatment and Research
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Single-cell and spatial transcriptomics
- Prostate Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Cancer, Lipids, and Metabolism
- Cancer Cells and Metastasis
- MicroRNA in disease regulation
- Bioinformatics and Genomic Networks
- RNA modifications and cancer
- Protease and Inhibitor Mechanisms
- Cancer-related gene regulation
- Gene expression and cancer classification
- Molecular Biology Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Ubiquitin and proteasome pathways
- BRCA gene mutations in cancer
- Bone and Dental Protein Studies
- Advanced Proteomics Techniques and Applications
- Peptidase Inhibition and Analysis
- Global Cancer Incidence and Screening
- AI in cancer detection
- Ferroptosis and cancer prognosis
Stanford University
2020-2025
Aarhus University Hospital
2013-2022
Palo Alto University
2020-2022
Stanford Health Care
2021
Aarhus University
2019-2020
King's College London
2016
Tampere University Hospital
2014
Tampere University
2014
Heinrich Heine University Düsseldorf
2014
Düsseldorf University Hospital
2014
Ductal carcinoma in situ (DCIS) is a pre-invasive lesion that thought to be precursor invasive breast cancer (IBC). To understand the changes tumor microenvironment (TME) accompanying transition IBC, we used multiplexed ion beam imaging by time of flight (MIBI-TOF) and 37-plex antibody staining panel interrogate 79 clinically annotated surgical resections using machine learning tools for cell segmentation, pixel-based clustering, object morphometrics. Comparison normal with patient-matched...
Abstract Purpose: Available tools for prostate cancer diagnosis and prognosis are suboptimal novel biomarkers urgently needed. Here, we investigated the regulation biomarker potential of GABRE∼miR-452∼miR-224 genomic locus. Experimental Design: GABRE/miR-452/miR-224 transcriptional expression was quantified in 80 nonmalignant 281 tissue samples. promoter methylation determined by methylation-specific qPCR (MethyLight) 35 nonmalignant, 293 [radical prostatectomy (RP) cohort 1] 198 samples (RP...
Citation: Siri Strand (2016). «The Hacked World Order: How Nations Fight, Trade, Maneuver, and Manipulate in the Digital Age». Bokanmeldelse, Internasjonal Politikk, 74, 4: 1–4. http://dx.doi.org/10.17585/ip.v74.622
Current diagnostic and prognostic tools for prostate cancer ( PC ) are suboptimal, leading to overdiagnosis overtreatment. Aberrant promoter hypermethylation of specific genes has been suggested as novel candidate biomarkers that may improve diagnosis prognosis. We here analyzed ST 6 GALNAC 3 ZNF 660 methylation in tissues, , CCDC 181 HAPLN liquid biopsies. First, using four independent patient sample sets, including a total 110 nonmalignant NM 705 tissue samples, by methylation‐specific...
Novel biomarkers for prostate cancer (PC) are urgently needed. This study investigates the expression, epigenetic regulation, and prognostic potential of ANPEP in PC. Aminopeptidase N (APN; encoded by ANPEP) expression was analysed immunohistochemistry using tissue microarrays representing 267 radical prostatectomy (RP) 111 conservatively treated (CT) PC patients. Clinical end points were recurrence-free survival (RFS) cancer-specific (CSS), respectively. The promoter methylation levels...
Prognostic tools for prostate cancer (PC) are inadequate and new molecular biomarkers may improve risk stratification. The epigenetic mark 5-hydroxymethylcytosine (5hmC) has recently been proposed as a novel candidate prognostic biomarker in several malignancies including PC. 5hmC is an oxidized derivative of 5-methylcytosine (5mC) can be further to 5-formylcytosine (5fC) 5-carboxylcytosine (5caC). present study the first investigate potential PC all four DNA methylation marks parallel....
Abstract Ductal carcinoma in situ (DCIS) is a risk factor for subsequent invasive breast cancer. To identify events DCIS that lead to cancer, we performed single-cell RNA-sequencing (scRNA-seq) on lesions and matched normal tissue. Inferred copy number variation (CNV) was used neoplastic epithelial cells from clinical specimens, which contained mixture of ducts. Phylogenetic analysis demonstrated intratumoral clonal heterogeneity associated with significant gene expression differences....
// Helen Ross-Adams 1 , Stephen Ball 2 Kate Lawrenson 3 Silvia Halim Roslin Russell Claire Wells 4 Siri H. Strand 5 Torben F. Ørntoft Melissa Larson 6 Sebastian Armasu Charles E. Massie Mohammad Asim Martin M. Mortensen 8 Michael Borre Kathryn Woodfine Anne Y. Warren 9 Alastair D. Lamb 1,10 Jonathan Kay 1,15 Hayley Whitaker Antonio Ramos-Montoya Adele Murrell 7 Karina Sørensen Brooke L. Fridley 11 Ellen Goode Simon A. Gayther John Masters David Neal 1,10,* and Ian G. Mills...
Prostate cancer (PC) diagnosis is based on histological evaluation of prostate needle biopsies, which have high false negative rates. Here, we investigated if cancer-associated epigenetic field effects in histologically normal tissue may be used to increase sensitivity for PC. We focused nine genes (AOX1, CCDC181 (C1orf114), GABRE, GAS6, HAPLN3, KLF8, MOB3B, SLC18A2, and GSTP1) known hypermethylated Using quantitative methylation-specific PCR, analysed 66 malignant 134 non-malignant samples...
New molecular biomarkers for prostate cancer (PC) prognosis are urgently needed. Ratio-based models attractive, as they require no additional normalization. Here, we train and independently validate a novel 4-miRNA prognostic ratio model PC.By genome-wide miRNA expression profiling of PC tissue samples from 123 men who underwent radical prostatectomy (RP) (PCA123, training cohort), identified six top candidate miRNAs systematically tested their ability to predict postoperative biochemical...
Prostate cancer (PCa) is a clinically heterogeneous disease and currently, accurate diagnostic prognostic molecular biomarkers are lacking. This study aimed to identify novel DNA hypermethylation markers for PCa with future potential blood-based testing. Accordingly, search genes specifically hypermethylated in tissue samples not blood cells or other types, we performed systematic analysis of genome-wide methylation data (Infinium 450K array) available the Marmal-aid database 4072...
Novel and minimally-invasive prostate cancer (PCa)-specific biomarkers are needed to improve diagnosis risk stratification. Here, we investigated the biomarker potential in localized de novo metastatic PCa (mPCa) of methylated circulating tumor DNA (ctDNA) plasma. Using Marmal-aid database in-house datasets, identified three top candidates specifically hypermethylated tissue: DOCK2, HAPLN3, FBXO30 (specificity/sensitivity: 80%–100%/75–94%). These were further analyzed plasma samples from 36...
Prostate cancer (PC) can be stratified into distinct molecular subtypes based on TMPRSS2-ERG gene fusion status, but its potential prognostic value remains controversial. Likewise, routine clinicopathological features cannot clearly distinguish aggressive from indolent tumors at the time of diagnosis; thus, new biomarkers are urgently needed. The DNA methylation variant 5-hydroxymethylcytosine (5hmC, an oxidized derivative 5-methylcytosine) has recently emerged as a diagnostic and/or...
Abstract Background Triple-negative breast cancer (TNBC) is an aggressive subtype that exhibits a high incidence of distant metastases and lacks targeted therapeutic options. Here we explored how the epigenome contributes to matrix metalloprotease (MMP) dysregulation impacting tumor invasion, which first step metastatic process. Methods We combined RNA expression chromatin interaction data identify insulator elements potentially associated with MMP gene invasion. employed CRISPR/Cas9 disrupt...
The lack of biomarkers that can distinguish aggressive from indolent prostate cancer has caused substantial overtreatment clinically insignificant disease. Here, by genome-wide DNA methylome profiling, we sought to identify new improve the accuracy diagnosis and prognosis.Eight novel candidate markers, COL4A6, CYBA, TCAF1 (FAM115A), HLF, LINC01341 (LOC149134), LRRC4, PROM1, RHCG, were selected Illumina Infinium HumanMethylation450 BeadChip analysis 21 tumor (T) non-malignant (NM) specimens....
miR-615-3p has previously been described as up-regulated in prostate cancer (PC) tissue samples compared with nonmalignant controls; however, its prognostic potential and functional role PC remain largely unknown. In this study, we investigated the clinical biological relevance of PC. The expression was measured specimens from 239 men who underwent radical prostatectomy (RP), it if could predict postoperative biochemical recurrence (BCR). These findings were subsequently validated three...
Abstract Ductal carcinoma in situ (DCIS) is a pre-invasive lesion that thought to be precursor invasive breast cancer (IBC). To understand how the tumor microenvironment (TME) changes with transition IBC, we used Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF) and 37-plex antibody staining panel analyze 140 clinically annotated surgical resections covering full spectrum progression. We compared normal, DCIS, IBC tissues using machine learning tools for multiplexed cell...
The current inability to predict whether a primary prostate cancer (PC) will progress metastatic disease leads overtreatment of indolent PCs as well undertreatment aggressive PCs. Here, we explored the transcriptional changes associated with progression multifocal hormone-naive PC.Using total RNA-sequencing, analysed laser micro-dissected PC foci (n = 23), adjacent normal tissue samples 23) and lymph node metastases 9) from ten patients. Genes important for were identified using differential...
Improved prognostic biomarkers are needed to guide personalized prostate cancer (PC) treatment decisions. Due the prominent molecular heterogeneity of PC, multimarker panels may be more robust. Here, 25 selected top‐candidate miRNA and methylation markers for PC were profiled by qPCR in malignant radical prostatectomy (RP) tissue specimens from 198 patients (Cohort 1, training). Using GLMnet, we trained a novel model (miMe) comprising nine miRNAs three that predicted postoperative...
Abstract Improved prostate cancer prognostic biomarkers are urgently needed. We previously identified the four-miRNA biomarker panel MiCaP ((miR-23a-3p × miR-10b-5p)/(miR-133a-3p miR-374b-5p)) for prediction of biochemical recurrence (BCR) after radical prostatectomy (RP). Here, we an optimal numerical cut-off dichotomisation using a training cohort 475 RP patients and tested this in independent 281 (PCA281). Kaplan–Meier, uni- multivariate Cox regression analyses were conducted multiple...
This study aimed to validate whether 5-hydroxymethylcytosine (5hmC) level in combination with ERG expression is a predictive biomarker for biochemical failure (BF) men undergoing radical prostatectomy (RP) prostate cancer (PCa). The included 592 PCa patients from two consecutive Danish RP cohorts. 5hmC and were analyzed using immunohistochemistry specimens. was scored as low or high negative positive. Risk of BF stratified cumulative incidences multiple cause-specific Cox regression...